Loading...
XNASINVO
Market cap3mUSD
Oct 21, Last price  
0.83USD
Name

INVO Bioscience Inc

Chart & Performance

D1W1MN
XNAS:INVO chart
P/E
—
P/S
1.08
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
45.39%
Rev. gr., 5y
43.62%
Revenues
3m
+267.38%
0037,99563,20467,64871,50356,37727,06316,58811,68950,901282,145494,3751,480,2131,037,2864,160,116822,1963,020,575
Net income
-8m
L-26.24%
-7,386-43,386-1,873,405-4,661,469-153,430-797,471-666,454-760,679-1,732,472-4,959,247-2,124,252-702,163-3,076,091-2,167,544-8,347,316-6,654,940-10,892,511-8,034,612
CFO
-5m
L-27.99%
-1,011-12,941-1,066,629-926,664-315,992-117,779-43,209-59,916-19,401-151,622-323,900-181,270-652,9711,370,513-4,775,148-6,029,914-6,603,319-4,755,054
Earnings
May 13, 2025

Profile

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
URL
https://invobioscience.com/
IPO date
Nov 11, 2008
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,021
267.38%
822
-80.24%
4,160
301.06%
Cost of revenue
2,100
876
361
Unusual Expense (Income)
NOPBT
920
(53)
3,799
NOPBT Margin
30.46%
91.31%
Operating Taxes
28
3
5
Tax Rate
3.02%
0.13%
NOPAT
892
(56)
3,794
Net income
(8,035)
-26.24%
(10,893)
63.68%
(6,655)
-20.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,702
290
3,651
BB yield
-269.72%
-5.64%
-10.31%
Debt
Debt current
1,907
994
222
Long-term debt
12,696
3,572
4,025
Deferred revenue
(2)
(1)
Other long-term liabilities
5,000
2
1
Net debt
11,283
3,238
(2,928)
Cash flow
Cash from operating activities
(4,755)
(6,603)
(6,030)
CAPEX
(445)
(13)
(455)
Cash from investing activities
(2,495)
(81)
(2,154)
Cash from financing activities
7,392
1,090
3,771
FCF
(173)
2,032
1,467
Balance
Cash
232
90
5,685
Long term investments
3,088
1,238
1,490
Excess cash
3,170
1,287
6,967
Stockholders' equity
(57,818)
(49,782)
(38,890)
Invested Capital
72,394
51,469
48,324
ROIC
1.44%
8.44%
ROCE
6.31%
40.26%
EV
Common stock shares outstanding
1,566
606
532
Price
1.35
-84.07%
8.48
-87.27%
66.60
10.63%
Market cap
2,114
-58.85%
5,138
-85.49%
35,406
114.27%
EV
19,397
8,375
32,478
EBITDA
1,121
253
3,965
EV/EBITDA
17.30
33.11
8.19
Interest
926
59
1,265
Interest/NOPBT
100.62%
33.31%